UBS Group
ASBP

UBS Group’s Aspire Biopharma ASBP Stock Holding History

UBS Group’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$197K Buy
6,383
+4,287
+205% +$228K ﹤0.01% 6644
2025
Q4 		$332K Buy
2,096
+2,090
+34,833% +$523K ﹤0.01% 6301
2025
Q3 		$1.58K Buy
+6
New +$3K ﹤0.01% 9315
2025
Q2 		– Sell
-25
Closed -$17.5K – 11117
2025
Q1 		$17.5K Buy
+25
New +$173K ﹤0.01% 8319
2024
Q4 		– Hold
0
– – – 9441
2024
Q3 		– Sell
-1
Closed -$8.75K – 10232
2024
Q2 		$8.75K Buy
+1
New +$13.6K ﹤0.01% 7781
2024
Q1 		– Hold
0
– – – 8481
2023
Q4 		– Hold
0
– -$650 – 10032
2023
Q3 		– Hold
0
– – – 8352
2022
Q4 		– Sell
-41
Closed -$497K – 11245
2022
Q3 		$497K Hold
41
– – ﹤0.01% 4349
2022
Q2 		$487K Buy
+41
New +$491K ﹤0.01% 4273

Other funds holding ASBP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return

UBS Group's ASBP Position: Q1 2026 in Review

UBS Group increased its Aspire Biopharma (ASBP) stake by 205% in Q1 2026, buying an estimated $228K and bringing the position to 6,383 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #6644.

UBS Group first reported a position in ASBP in Q2 2022 and has held it in 7 quarters since. The position peaked at $497K in Q3 2022. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • UBS Group held 6,383 shares of Aspire Biopharma worth $197K as of Q1 2026.
  • UBS Group bought 4,287 Aspire Biopharma shares in Q1 2026, an estimated $228K.
  • Aspire Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6644 holding.
  • UBS Group first reported a position in Aspire Biopharma in Q2 2022 and has held it in 7 quarters since.
  • UBS Group's Aspire Biopharma position peaked at $497K in Q3 2022.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.